Clinical and economic benefits of pharmacist interventions in a non–multiple sclerosis neurology clinic
American Journal of Health-System Pharmacy · 19.08.2026 · 83 (17) · e691-e698
DOI: 10.1093/ajhp/zxag088 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Health-System Pharmacy, online erschienen am 20.03.2026. Verfasst von Kayla Johnson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt Specialty Pharmacy, Vanderbilt Health System, Nashville, TN, USA. Hauptthemen laut MEDLINE: Pharmacists, Neurology. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Purpose
To examine interventions, recommendations, and direct cost avoidance from integrated outpatient specialty neurology pharmacists in the non–multiple sclerosis (MS) setting.
Methods
A single-center, retrospective cohort study was performed, including patients prescribed specialty medications from non-MS neurology clinics with at least one pharmacist intervention from January to March 2023. Outcomes included pharmacist intervention types, intervention recommendations to patients and providers, and direct cost avoidance from interventions. Cost avoidance was calculated by summing the total costs (average wholesale price minus 20%) of one fill of medications that were discontinued or had a dose change as a result of an intervention or refill deferral. Patients who used excess supply on hand from a previous fill were accounted for during the calculation. The cost per unit of each medication/dosage was multiplied by the quantity of the last medication fill to calculate the cost avoided.
Results
The study included 741 patients with a median age of 60 (interquartile range, 22-72) years; 83% were White; 55% were male; and 69% used the integrated health-system specialty pharmacy (IHSSP) for medication fulfillment. Pharmacists performed 2,244 interventions, generating 392 recommendations, with a 98% acceptance rate. The most common recommendation outcomes were medication changes (34%, n = 129) and financial assistance referrals (17%, n = 64). During the 3-month study period, discontinuations and dose changes resulted in $172,757 in direct cost avoidance for IHSSP patients.
Conclusion
IHSSP neurology pharmacists in the non-MS setting frequently perform interventions that result in therapy changes and direct cost avoidance. IHSSP pharmacist interventions benefit patients, providers, the healthcare system, and insurers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Vanderbilt Specialty Pharmacy, Vanderbilt Health System, Nashville, TN, USA.
- University of Tennessee Health Science Center College of Pharmacy, Knoxville, TN, USA.
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
ORCID-Profile: Leena Choi
Zitieren
APA
Johnson, K., Kaveh, M., Livezey, S., Moore, R., Choi, L., Zuckerman, A. D., & Cruchelow, K. (2026). Clinical and economic benefits of pharmacist interventions in a non–multiple sclerosis neurology clinic. American Journal of Health-System Pharmacy, 83(17), e691-e698. https://doi.org/10.1093/ajhp/zxag088
Vancouver
Johnson K, Kaveh M, Livezey S, Moore R, Choi L, Zuckerman AD, et al. Clinical and economic benefits of pharmacist interventions in a non–multiple sclerosis neurology clinic. American Journal of Health-System Pharmacy. 2026;83(17):e691-e698. doi:10.1093/ajhp/zxag088
BibTeX
@article{Johnson2026,
author = {Johnson, Kayla and Kaveh, Morteza and Livezey, Sabrina and Moore, Ryan and Choi, Leena and Zuckerman, Autumn D and Cruchelow, Katie},
title = {Clinical and economic benefits of pharmacist interventions in a non–multiple sclerosis neurology clinic},
journal = {American Journal of Health-System Pharmacy},
year = {2026},
volume = {83},
number = {17},
pages = {e691--e698},
doi = {10.1093/ajhp/zxag088}
}
EUVIMED